Prognostic factors for survival in dogs with pituitary-dependent hypercortisolism treated with trilostane.
Vet Rec
; 176(2): 49, 2015 Jan 10.
Article
in En
| MEDLINE
| ID: mdl-25170036
ABSTRACT
Pituitary-dependent hypercortisolism (PDH) is one of the most frequent endocrinopathies in dogs, but prognostic factors are largely unknown. The aim of this retrospective case series study was to determine the prognostic value of different clinical and clinicopathological variables evaluated in dogs newly diagnosed with PDH that were subsequently treated with trilostane. Medical records from one referral centre were evaluated. Eighty-five dogs with PDH were included. The median survival time was 852â
days (range 2-3210â
days); 60/85 (70 per cent) and 25/85 (29 per cent) dogs survived more than one and three years, respectively. In multivariable model analysis the length of survival of older dogs (HR 1.24, 95% CI 1.09 to 1.40) and dogs with higher serum phosphate concentrations (HR 1.35, 95% CI 1.01 to 1.81) was shorter. Serum phosphate concentrations were above the reference range in 37/85 (44 per cent) of animals. Clinical signs, liver enzymes, serum cortisol concentrations of the endocrine tests, proteinuria, systolic hypertension, the presence of concomitant disorders, and the frequency of trilostane administration were not associated with survival time. Hyperphosphataemia is a common finding in dogs with newly diagnosed PDH and represents a negative prognostic factor.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Dihydrotestosterone
/
Pituitary ACTH Hypersecretion
/
Dog Diseases
/
Enzyme Inhibitors
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Animals
Language:
En
Journal:
Vet Rec
Year:
2015
Document type:
Article
Affiliation country: